Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equecabtagene Autoleucel (Eque-cel) BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
jRCT2033250761Phase 2Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- Mar 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Reindeer Biotech. Primary endpoints: Safety (Part 1) and Overall response rate by IRC (Part 2). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2033250761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250761.